<SEC-DOCUMENT>0001140361-21-033449.txt : 20211004
<SEC-HEADER>0001140361-21-033449.hdr.sgml : 20211004
<ACCEPTANCE-DATETIME>20211004160210
ACCESSION NUMBER:		0001140361-21-033449
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20211001
FILED AS OF DATE:		20211004
DATE AS OF CHANGE:		20211004

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Benton Susan
		CENTRAL INDEX KEY:			0001373649

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34079
		FILM NUMBER:		211302644

	MAIL ADDRESS:	
		STREET 1:		3916 VALRICO GROVE DRIVE
		CITY:			VALRICO
		STATE:			FL
		ZIP:			33594

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocuphire Pharma, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		37000 GRAND RIVER AVE.
		STREET 2:		SUITE 120
		CITY:			FARMINGTON HILLS
		STATE:			MI
		ZIP:			48335
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		37000 GRAND RIVER AVE.
		STREET 2:		SUITE 120
		CITY:			FARMINGTON HILLS
		STATE:			MI
		ZIP:			48335

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-10-01</periodOfReport>

    <issuer>
        <issuerCik>0001228627</issuerCik>
        <issuerName>Ocuphire Pharma, Inc.</issuerName>
        <issuerTradingSymbol>OCUP</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001373649</rptOwnerCik>
            <rptOwnerName>Benton Susan</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O OCUPHIRE PHARMA, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>37000 GRAND RIVER AVE, SUITE 120</rptOwnerStreet2>
            <rptOwnerCity>FARMINGTON HILLS</rptOwnerCity>
            <rptOwnerState>MI</rptOwnerState>
            <rptOwnerZipCode>48335</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-10-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>2135</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>26111</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The Reporting Person was granted common stock in lieu of cash for Q3 2021 Board services.  The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share).  The Fair Market Value was $5.15 per share, the closing price of the Company's stock on September 30, 2021.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Emily J. Johns, by Power of Attorney</signatureName>
        <signatureDate>2021-10-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
